Oncology Drugs Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Actuate Therapeutics and the Rise of Regional Oncology Biotech Hubs

Parabilis Medicines IPO Supports Cancer Drug Pipeline Targeting “Undruggable” Proteins

FDA Clears AbbVie’s Decnupaz for Ultra-Rare Blood Cancer BPDCN

New FDA Guidance Could Reduce Animal Testing for Some Cancer Drugs

Clinical Trial News

AstraZeneca’s Camizestrant Hit by FDA Advisory Committee Vote While Truqap Moves Ahead

Lifyorli (Relacorilant) Combo FDA-Approved for Platinum-Resistant Ovarian Cancer

Eikon Therapeutics IPO Brings in $381M for Oncology Pipeline

Rethinking Endocrine Therapy in ER-Positive Breast Cancer

Roche’s Subcutaneous Lunsumio Velo Receives FDA Approval for Follicular Lymphoma

January 21, 2026

FDA Approves Enhertu-Perjeta Combo as First-Line Treatment for HER2-Positive Breast Cancer

January 20, 2026

Bayer’s Hyrnuo Wins FDA Approval for HER2-Mutated NSCLC, Joins Boehringer’s Hernexeos in the Space

December 23, 2025

Breyanzi Wins Expanded FDA Approval as First CAR T-Cell Therapy for Marginal Zone Lymphoma

December 9, 2025

“Game-Changing” Keytruda-Padcev Combo Gets FDA Nod for Muscle-Invasive Bladder Cancer

December 4, 2025

Akeso’s Ivonescimab Shows OS Benefit in EGFR-Mutant NSCLC

November 28, 2025

Komzifti Approved as Second Oral Menin Inhibitor for NPM1-Mutated AML After Revuforj

November 21, 2025

Blenrep Combination Wins FDA Nod in Relapsed or Refractory Multiple Myeloma

October 24, 2025

Next Page »